Yarrow Biotechnology, Inc.
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Yarrow Biotechnology, Inc.
ProQR Remains Confident In Pipeline After Sepofarsen Flop, Analysts Not So Much
The company is pinning hopes on its Usher syndrome and retinitis pigmentosa programs, but the disconnect between Phase I/II success and Phase II/III failure dented analysts’ enthusiasm.
Lilly To Try ProQR’s RNA-Editing Technology In Liver, Neurology Indications
ProQR’s Axiomer platform can enable single nucleotide RNA editing, an approach that could address thousands of disease-causing genetic mutations, the company says.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Yarrow Biotechnology, Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice